MON-166 Preclinical characterization of a highly potent and selective HSD17B1 inhibitor for the treatment of endometriosis
OA: gold
AI-generated summary
MON-166, a potent and selective HSD17B1 inhibitor, demonstrated efficacy in preclinical models of endometriosis by targeting a key enzyme involved in estrogen metabolism.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-09-27T09:11:36.575535+00:00